Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (BRCA-P)
Enrolling By Invitation
25-55 years
Female
Phase
3
300 participants needed
1 Location
Brief description of study
This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Breast Cancer
-
Age: Between 25 Years - 55 Years
-
Gender: Female
Females Age 25-55 Confirmed deleterious or likely deleterious BRCA 1 germline mutation
Updated on
01 Aug 2024.
Study ID: 851430
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
